"I am excited to join Envisagenics at this pivotal stage in the company's development," said Sudhir Rao. "The company's cutting-edge, AI-driven SpliceCore® platform identifies novel targets, paving the way for innovative treatments in oncology, neurodegenerative diseases, and beyond. I look forward to collaborating with the talented team to execute impactful partnerships, expand our relationships with investors and enable the development of groundbreaking therapies for patients."